CKD Prevalence Varies across the European General Population
Katharina Brück(European Hematology Association), Kitty J. Jager(Amsterdam University Medical Centers), Dorothea Nitsch(London School of Hygiene & Tropical Medicine), Stein Hallan(Norwegian University of Science and Technology), Solfrid Romundstad(Norwegian University of Science and Technology), Gerjan Navis(University Medical Center Groningen), Henry Völzke(Universitätsmedizin Greifswald), Jean Ferrières(Université Fédérale de Toulouse Midi-Pyrénées), Christoph Wanner(Universitätsklinikum Würzburg), Giovanni Gambaro(University of Verona), Johan Ärnlöv(Dalarna University), Jerzy Chudek(Medical University of Silesia), Carmine Zoccali(Biogem), Vianda S Stel(Amsterdam UMC Location University of Amsterdam), José Vinhas(Hospital de São Bernardo), Bénédicte Stengel(Inserm), Pietro Manuel Ferraro(Università Cattolica del Sacro Cuore), Hermann Brenner(Universidad de Granada), Mika Kastarinen(Finnish Medicines Agency Fimea), Dietrich Rothenbacher(Helmholtz-Institute Ulm), Luigi Palmieri(Istituto Superiore di Sanità), Idris Guessous(University of Geneva), Charles Tomson(Freeman Hospital), Vincenzo Capuano, Wim Van Biesen(Ghent University Hospital), Gemma Browne(University College Cork), Ron T. Gansevoort(University Medical Center Groningen), Alfonso Otero González, Aminu K. Bello(University of Alberta)
Cited by 588
Related Papers
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
|JAMA Oncology|2016|6.3k
Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2019|5.7k
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.1k
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet|2017|4.9k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k